Connect
← Return to High anxiety regarding Reclast or Prolia decison for OP meds
Discussion
High anxiety regarding Reclast or Prolia decison for OP meds
Osteoporosis & Bone Health | Last Active: Sep 22 4:39pm | Replies (165)Comment receiving replies
@255anny My osteoporosis doctor has suggested I follow Evenity with Prolia and then go back and forth between Evenity and Prolia. I asked about his experience with that and he said he has patients who have gone Evenity - Prolia - Evenity but no further so far as Evenity hasn't been around long enough to have gone further. He mentioned 2 years on Prolia.
I know of no studies following this kind of strategy and I wonder about following Prolia with Evenity. I'm don't know if there are any studies showing that is safe. Would Evenity protect from the fracture danger when stopping Prolia? He does not seem to worry about that but I haven't posed the question to him. Many docs seem unaware or unconcerned about those multiple fractures. I don't get that at all.
Replies to "@255anny My osteoporosis doctor has suggested I follow Evenity with Prolia and then go back and..."
Connect
My concern exactly - that Evenity doesn't fully or at all, protect from the risk of stopping the short term use of Prolia. Interesting that your Dr is suggesting the Evenity >. Prolia > Evenity that my Dr. is/had ordered for me, except the Prolia was to be for 1 year. I have spent over 2 weeks researching for studies or anything that points to this drug sequence as an accepted protocol. There is nothing definitive that states this is ok. I don't want to question my Dr's expertise in Osteoporosis management, but quite honestly I am. I am still waiting for a response from this Dr - nothing so far. Adding the below conclusion of a study.
" In conclusion, romosozumab appears to maintain or improve the gains in BMD after a 12‐month course of denosumab treatment in postmenopausal women with low bone mass, while levels of BTMs gradually return to baseline levels. The sequence of romosozumab after denosumab is not as effective in increasing BMD as is the opposite sequence of using romosozumab first. Larger studies in women at high fracture risk are needed to determine the true clinical impact and utility of the treatment sequence of denosumab followed by romosozumab."